AstraZeneca lupus drug makes comeback to meet main goal at Phase 3
pharmafile | August 29, 2019 | News story | Research and Development | AstraZeneca, Lupus, anifrolumab, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint in the treatment of systemic lupus erythematosus (SLE).
The new findings revealed that patients taking anifrolumab, combined with standard of care, achieved a statistically-significant and clinically-meaningful reduction in disease activity versus placebo plus standard of care, as measured by British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) after 52 weeks of treatment.
These latest data represent a turning point from the failure of the therapy last year to meet its primary goal in a late stage trial.
“As clinicians we need new medicines for this complex and difficult-to-treat disease,” commented Professor Eric F Morand of Monash University, and Principal Investigator on the TULIP 2 trial. “These exciting results from the TULIP 2 trial demonstrate that, by targeting the type I interferon receptor, anifrolumab reduced disease activity in patients with systemic lupus erythematosus.”
LSE is an autoimmune condition in which the body’s immune system attacks its own healthy tissues, leading to organ damage as well as fatigue, rashes, pain, fever and swelling of joints; those living with the disease are also more susceptible to death from infection and cardiovascular disease.
In the last six decades, there has only been one new therapy approved for the disease.
Matt Fellows
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …
